Bezetabart debotansine

得坦贝泽妥拜单抗

Report date: 2024/07/03 15:54:18

Base Information

Drug NameBezetabart debotansine
Drug Alias NameSTRO-001BN-301SP7675SP-7675
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > DBCO linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Maytansine derivative payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CD74Tubulin inhibitors
TargetsHLA-DR antigens-associated invariant chainTubulin
Therapy Area/IndicationsHematologic NeoplasmsMultiple MyelomaLymphoma, Mantle-Cell +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSutro Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesBionova Pharmaceuticals (Shanghai) LtdSutro Biopharma Inc
Inactive CompaniesPiramal Pharma Solutions Inc
Active IndicationsHematologic NeoplasmsMultiple MyelomaLymphoma, Mantle-Cell +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A